Author

Marco Pergher

Observed names: M. Pergher, Pergher, Marco

Institution: Aptuit (Italy)

Observed institutions: Aptuit (Italy), Evotec (United Kingdom), Evotec (United States)

OpenAlex ID: A5075801611

Characterization and translational development of IOA-289, a novel autotaxin inhibitor for the treatment of solid tumors

2023 · M.A. Deken, K. Niewola-Staszkowska, et al. · Immuno-Oncology Technology · 27

Blood microsampling in cynomolgus monkey and evaluation of plasma PK parameters in comparison to conventional sampling

2023 · Simone Bertani, Alberto Donadi, et al. · Journal of Pharmacological and Toxicological Methods · 4

A modeling-based framework to evaluate forgiveness of tuberculosis treatment in a BALB/c relapsing mouse model

2026 · Sylvie Sordello, Laure Brock, et al. · Antimicrobial Agents and Chemotherapy · 3

Nonclinical pharmacokinetics and relative efficacy of the first 25 novel tuberculosis drug combinations from the PAN-TB consortium: Use of the BALB/c relapsing mouse model and combination pharmacokinetics within a modeling-based framework

2026 · Sylvie Sordello, Alessia Tagliavini, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 1

131P Translating a novel autotaxin inhibitor from preclinical proof of concept in pancreatic cancer to a biomarker response in human subjects

2021 · S. Milleri, M. Deken, et al. · Annals of Oncology · 1

Impact of GPR39 Inhibition on Tissue Oxygen Tension in Acute Myocardial Infarction: Modeling Using an Indirect Response Pharmacokinetics/Pharmacodynamics Approach

2026 · Davide Ronchi, Chiara Roversi, et al. · bioRxiv (Cold Spring Harbor Laboratory)

Next Generation TB Drug Combinations from the Pan-TB Consortium: Combination Efficacy and Contributions of Individual Agents, Evaluated in a BALB/c Mouse TB Model

2026 · Sylvie Sordello, Alain Le Coupanec, et al. · bioRxiv (Cold Spring Harbor Laboratory)

Enhancing dose selection in phase I cancer trials: Extending the Bayesian Logistic Regression Model with non-DLT adverse events integration

2025 · Andrea Nizzardo, Luca Genetti, et al. · Journal of Biopharmaceutical Statistics

Abstract CT088: EVT801, a novel selective VEGFR-3 inhibitor targeting tumor angiogenesis, is pursuing dose escalation stage of phase I first-in-human study

2024 · Carlos Gomez-Roca, Philippe Cassier, et al. · Cancer Research

Abstract 2636: Targeting Autotaxin to suppress stromal signaling in the tumor microenvironment to improve outcome to therapy in fibrotic tumor types

2022 · Zoe Johnson, Marcel Deken, et al. · Cancer Research

Determinazione Dell'origine Botanica Del Miele: Un Nuovo Ed Affidabile Metodo Di Risonanza Magnetica Nucleare E Chemiometria

2009 · Marco Pergher

Works count: 12

Citation count: 36

H-index: 3

I10-index: 1